Open AccessThe Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris
Author(s) -
Nathan P. Wiederhold,
Laura K. Najvar,
Rosie Jaramillo,
Marcos Olivo,
Hoja Patterson,
April Connell,
Yoshiko Fukuda,
Junichi Mitsuyama,
Gabriel Catano,
Thomas F. Patterson
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02198-19
Subject(s) - in vivo , in vitro , candida auris , microbiology and biotechnology , chemistry , pharmacology , medicine , biology , biochemistry , antifungal
The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log 10 CFU/g) compared to control (0% survival and 7.09 log 10 CFU/g) ( P < 0.01).